REGENXBIO
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell REGENXBIO and other ETFs, options, and stocks.About RGNX
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381.
CEOCurran M. Simpson
CEOCurran M. Simpson
Employees353
Employees353
HeadquartersRockville, Maryland
HeadquartersRockville, Maryland
Founded2008
Founded2008
Employees353
Employees353
RGNX Key Statistics
Market cap455.64M
Market cap455.64M
Price-Earnings ratio-2.60
Price-Earnings ratio-2.60
Dividend yield—
Dividend yield—
Average volume776.65K
Average volume776.65K
High today$9.09
High today$9.09
Low today$8.07
Low today$8.07
Open price$8.15
Open price$8.15
Volume1.34M
Volume1.34M
52 Week high$13.48
52 Week high$13.48
52 Week low$5.04
52 Week low$5.04
RGNX News
TipRanks 5d
FDA Extends Review for RegenXBio’s RGX-121 TherapyElevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...
Analyst ratings
92%
of 13 ratingsBuy
92.3%
Hold
7.7%
Sell
0%
People also own
Based on the portfolios of people who own RGNX. This list is generated using Robinhood data, and it’s not a recommendation.